U.S. company licenses rights to long-acting testosterone preparation
Indevus Pharmaceuticals, Inc., Lexington, MA has licensed exclusive U.S. rights from Schering AG, Germany to market Nebido, a long-acting injectable testosterone preparation for the treatment of male hypogonadism.
Indevus Pharmaceuticals, Inc., Lexington, MA has licensed exclusive U.S. rights from Schering AG, Germany to market Nebido, a long-acting injectable testosterone preparation for the treatment of male hypogonadism. Nebido, which was recently approved and launched in Europe, requires dosing only once every 3 months.
Under the agreement, Indevus will be responsible for the development and commercialization of the drug in the United States. Schering will be responsible for manufacturing and supplying commercial product to Indevus.
Indevus said it currently anticipates filing a new drug application with the FDA in the second half of 2006.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
